Propanc Pty Ltd.

MELBOURNE, Australia--( BUSINESS WIRE )-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s Joint Researcher, Mrs. Belén Toledo Cutillas, MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Spain, received an award for best poster at the “Doctoral Days 2022 for Young Researchers of the University of Jaén,” conference. The poster, entitled, “ Blocking Tumor Support from Cancer Associated Fibroblasts in Tumor Microenvironment ,” describes a novel therapeutic strategy to decrease tumor microenvironment (TME) influence in drug uptake, immune evasion, tumor progression and further tumor dispersion. A copy of the publication can be accessed from the Company’s website, via the following link: https://www.propanc.com/news-media/publications . Despite cancer research budgets continuing to grow, and even with knowledge of the complex interaction between a tumor and its host organism, standard treatments are still inefficient, which continues to lead to extremely serious side effects and to the development of tumor relapses due to acquired chemoresistance. Cancer Associated Fibroblasts (CAFs), as the main cell population of the TME, play a key role in all stages of tumorigenesis, from tumor initiation to the induction of the pre-metastatic niche settlement; thus, it appears to seem evident that novel therapeutic approaches should hamper CAFs support to tumor cells. “In addition to the serious side effects from standard treatment, which we all acknowledge, the biggest question facing cancer sufferers is whether the cancer will return, post-treatment. This recurrence often results from acquired chemoresistance as a result of the influence toward the tumor microenvironment from CAFs,” said Dr. Julian Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer and Cofounder. “Belén’s pioneering work in this field demonstrates that Propanc’s PRP can potentially impact chemoresistance from solid tumors by altering the TME, thus decreasing the risk of tumor recurrence, one of the biggest issues facing patients today. We continue to work closely with Belén and the team at the laboratory of Professor Perán, as we progress to a First-In-Human study in advanced cancer patients and investigate possible new clinical applications for PRP in combination with standard treatment approaches.” PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. About Propanc Biopharma, Inc. Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com . The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video . Forward-Looking Statements All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target,” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties, and other factors, that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that, as of the date of this press release, it would have substantial difficulty repaying in cash; the Company’s ability successfully to remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms on an as-needed basis; the Company’s ability successfully to initiate and complete clinical trials and to develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions; competition; and other risks, including, but not limited to, those described in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov . These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

Aug. 3, 2022 13:00 UTC Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jaén and Granada, Spain. Since late 2020, Mrs. Belén Toledo Cutillas MSc, has been investigating an important experimental thesis on the effects of proenzyme therapy and the impact on the tumor microenvironment, which is key to the development, invasion, metastatic spread and recurrence of solid tumors. The work is being conducted at the laboratory of Professor Macarena Perán PhD, who is the lead researcher on the project and is the second Joint Research Collaboration Agreement currently in progress with the two Spanish Universities. To date, encouraging results demonstrates that proenzymes have specific effects on tumor cells and CSCs, but also other tumor elements in the tumor microenvironment. However, the most significant conclusion is that proenzymes cause a reversal of the malignant phenotype (observable characteristics) towards a normal, or benign state. This process of reversing the tumor phenotype, called differentiation, is how proenzymes exert anti-tumor, anti-cancer and anti-metastatic effects. Therefore, proenzyme treatment may be considered differentiation therapy, which exerts these effects on malignant cells, but leaves healthy cells alone. To achieve these results, Mrs. Cutillas used integrated 3-dimensional bio-impressions of tumor cells from patients with advanced solid tumors, developed at the Centre for Biomedical Research, University of Granada, led by Professor Juan Marchal MD. Along with lead researcher, Professor Perán, and Mrs. Cutillas, additional research team members from the University of Jaén are assisting on the project, as well as Professor Marchal and Dr Maria Angel Garcia, from the University of Granada. Propanc will own any intellectual property developed during the research, and publishing rights, in exchange for any net future royalties from intellectual property rights. Dr Julian Kenyon, Md, MB, ChB, Propanc’s Chief Scientific Officer said, “Evaluating the effects of proenzyme therapy in the tumor microenvironment is of scientific interest, as it demonstrates whether proenzymes penetrate into this target area and exert its effects. At the same time, it confirms the selectivity of the drug on solid tumors, by targeting cancer cells and leaving healthy cells alone. The clinical implications are also potentially significant, which may result in novel discoveries and lead to exciting new ways to treat cancer patients suffering from solid tumors without the toxicity normally associated with standard treatment regimens.” “Continuing to expand our research efforts in the use of proenzymes and cancer leading to the identification of further discoveries can provide additional patentable subject matter and expand our intellectual property portfolio, which covers the invention relating to our lead product candidate, PRP. I look forward to working closely with Professor Perán and her team on this exciting project,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers. About Propanc Biopharma, Inc. Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit . The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: Forward-Looking Statements All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that it is unable to repay in cash; the Company’s ability to successfully remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at . These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。   引言2022年7月19日，总部位于澳大利亚的Propanc Biopharma,Inc. 宣布通过POP1（Proenzyme Optimization Project 1）联合研究和药物发现计划成功生产了合成重组版本的酶原胰蛋白酶原。该项目旨在为公司的主要候选产品PRP生产备用临床化合物，用于实体瘤的转移性癌症。   PRPPRP是两种由牛胰腺提取的酶原，胰蛋白酶原和胰凝乳蛋白酶原的混合物，具有逆转从上皮表型向间充质表型转变的能力，从而降低肿瘤的转移潜力。皮间质转化（epithelial to mesenchymal transition，EMT）是一种能够显著增强细胞迁移能力的生物过程，上皮细胞通过转化为间充质特征的细胞，并获得后者的运动性。上皮间质转化不仅关系到胚胎发育、伤口愈合等重要生命过程，还影响肿瘤的发展和转移。上皮间质转化可促使肿瘤细胞脱离原发性肿瘤位点、迁移到身体的其他部位，即让肿瘤细胞获得迁移和侵袭能力，发生恶性演变。基于此，PRP的主要目标是转移性癌症，其以1:6的协同比注射可以抑制大多数肿瘤细胞的生长，包括肾癌、卵巢癌、乳腺癌、脑癌、前列腺癌、结肠直肠癌、肺癌、肝癌、子宫癌和皮肤癌。   研发故事根据Emergen Research的数据，到2027年，全球转移性癌症市场预计价值1110亿美元。而Propanc致力于胰腺技术，为这些患有复发性和转移性癌症的患者提供治疗方案。目前，PRP配方中主要使用的是来自动物的天然酶原衍生品。Propanc之前就尝试合成重组胰蛋白酶原，但是酶原是一种复杂的生物大分子，在实验室生产时会影响其稳定性，难以用于商业用途。而POP1 计划的目标是生产大量用于商业用途的胰蛋白酶原和胰凝乳蛋白酶原，其具最小的批次间差异，并且无需从动物中提取。于是，POP1的负责人Aitor González，咨询了维也纳自然资源与生命科学大学微生物生物技术研究所的Diethard Mattanovich教授，准备进行更大规模的重组胰蛋白酶原生产，对其进行纯化以达到更高质量。“我们的目标是引入一种新的治疗方法来治疗通过使用酶原靶向和根除癌症干细胞来预防转移性癌症。我们希望确保利用天然衍生的酶原有效抗癌的同时，减少批次之间的差异并提高稳定性。就像礼来公司在1920年代首次将猪胰岛素引入患者以大规模治疗糖尿病一样，50年后，礼来公司继续生产合成的‘人’胰岛素。”Propanc的首席科学官兼联合创始人Julian Kenyon说。参考来源：[1] https://www.propanc.com/technology[2] https://www.cas.cn/syky/202203/t20220307_4827266.shtmlPR 稿对接：邮箱 acgt@pharnex.com靶点社 靶点江湖 · 新药际会PR | 品牌推广 | 会议会展 | 行业咨询靶点社ACGT「靶点社，汇聚50,000+创新药英雄」